Edmund Harrigan

Edmund Harrigan (board member) discloses dealings in 4 companies, chiefly Incyte Corp, Acadia Pharmaceuticals Inc and Karuna Therapeutics, Inc. Over a trading history stretching from 16 August 2016 to 30 September 2026, the count stands at 48 filings.

Market trades split into 2 purchases (€50k) and 3 sales (€4.0M). On balance, insiders were net sellers of €3.9M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 36 share grants and 7 option exercises.

The record was last updated on 2 October 2026 with a share grant (€22k) in Incyte Corp. The last purchase on record was published on 4 December 2020, which is 2,150 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.